Titleist Asset Management LLC bought a new stake in ARK Genomic Revolution ETF (BATS:ARKG – Free Report) in the second quarter, Holdings Channel.com reports. The institutional investor bought 8,800 shares of the company’s stock, valued at approximately $214,000.
Several other hedge funds and other institutional investors have also modified their holdings of the business. LPL Financial LLC raised its position in ARK Genomic Revolution ETF by 13.4% during the first quarter. LPL Financial LLC now owns 783,702 shares of the company’s stock valued at $16,270,000 after buying an additional 92,444 shares during the period. Clearwater Capital Advisors LLC lifted its position in shares of ARK Genomic Revolution ETF by 24.0% in the first quarter. Clearwater Capital Advisors LLC now owns 195,875 shares of the company’s stock worth $4,066,000 after purchasing an additional 37,970 shares in the last quarter. Raymond James Financial Inc. boosted its holdings in shares of ARK Genomic Revolution ETF by 65.4% during the first quarter. Raymond James Financial Inc. now owns 142,362 shares of the company’s stock worth $2,955,000 after purchasing an additional 56,283 shares during the period. Next Capital Management LLC purchased a new position in ARK Genomic Revolution ETF during the second quarter valued at approximately $318,000. Finally, Simplex Trading LLC purchased a new stake in ARK Genomic Revolution ETF in the 2nd quarter worth approximately $936,000.
ARK Genomic Revolution ETF Trading Up 28.8%
Shares of BATS:ARKG opened at $30.42 on Tuesday. ARK Genomic Revolution ETF has a 1 year low of $17.51 and a 1 year high of $31.16. The business has a fifty day simple moving average of $29.28 and a 200 day simple moving average of $25.85.
ARK Genomic Revolution ETF Profile
The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.
Further Reading
- Five stocks we like better than ARK Genomic Revolution ETF
- Find and Profitably Trade Stocks at 52-Week Lows
- A Trillion-Dollar Pill: Eli Lilly Broke the Healthcare Ceiling
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 5 Retail Stocks That Could Deck the Halls—or Wreck Portfolios
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- D-Wave: Time to Buy the Dip? Or is the Fall Just Starting?
Want to see what other hedge funds are holding ARKG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARK Genomic Revolution ETF (BATS:ARKG – Free Report).
Receive News & Ratings for ARK Genomic Revolution ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARK Genomic Revolution ETF and related companies with MarketBeat.com's FREE daily email newsletter.
